Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
← All stories
Federal PolicyJuly 2, 2026

DEA Proposes Schedule I Classification for Synthetic Kratom Compound 7-OH

The Drug Enforcement Administration announced plans to temporarily classify 7-hydroxymitragynine (7-OH) and three related synthetic kratom compounds as Schedule I controlled substances, placing them in the same regulatory category as heroin and LSD. The classification applies to synthetic versions of the psychoactive compound found in kratom products. If finalized, the scheduling action would prohibit manufacture, distribution, and possession of these substances, with enforcement implications for entities handling these compounds. The timing of implementation and comment period was not specified in the available content.

Why it mattersMedicaid MCOs covering behavioral health or substance use disorder treatment may need to update formularies, prior authorization protocols, and member communications if kratom-containing products are used by enrollees for pain or opioid withdrawal management.

Behavioral Health · Pharmacy

Read the full article at thehill.com →
Share this briefing

You might also like

← All stories

Get the daily briefing.